Skip to main content
SpringerLink
Log in

The Role of the Adrenal Glands in the Hyperandrogenism Associated with Polycystic Ovarian Syndrome

  • Chapter
  • First Online:
Polycystic Ovary Syndrome

Abstract

The magnitude of adrenal versus ovarian or peripheral contributions to the hyperandrogenemia of polycystic ovarian syndrome (PCOS) is controversial. Evidence for an adrenal origin of circulating androgens has been studied in prepubertal, adult, and postmenopausal women who will have, do have, or have had PCOS. Many girls who have premature adrenarche with increased circulating levels of adrenal steroid DHEA-S or those diagnosed with precocious puberty go on to develop PCOS in adolescence. Some adults with PCOS demonstrate increased DHEA and DHEA-S levels after ACTH stimulation test. Alternatively, or in addition, in many women with PCOS who have elevated DHEA or DHEA-S, these steroids may be suppressed by exogenous corticosteroid administration. In some PCOS women (20 %), long-term suppression of ovarian steroidogenesis to castrate levels with the use of GnRH agonists fails to suppress hyperandrogenemia, suggesting an adrenal source. Approximately 30–50 % of PCOS patients can be shown by these maneuvers to be producing excessive amounts of adrenal androgens. Increased activity of P450C17α can contribute to excessive production of both adrenal (DHEA) and ovarian (androstenedione) androgens. Alternatively, excess androgen production may occur as an ancillary phenomenon during processes that can result in cortisol overproduction (e.g., Cushing syndrome) or increased degradation of cortisol. The normal decline in adrenal androgen production with menopause is blunted in women who have PCOS and postmenopausal women with a history of PCOS demonstrate an exaggerated androgen response to exogenous ACTH. While the exact mechanisms remain unclear, these observations suggest that adrenal steroidogenesis may be under different control in women with PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.

    Article  PubMed  CAS  Google Scholar 

  2. Futterweit W, editor. Polycystic ovarian disease. Berlin: Springer; 1984.

    Google Scholar 

  3. Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012;97(12):4429–38.

    Article  PubMed  CAS  Google Scholar 

  4. Tiosano D, Vlodavsky E, Filmar S, Weiner Z, Goldsher D, Bar-Shalom R. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Horm Res Paediatr. 2010;74(3):223–8.

    Article  PubMed  CAS  Google Scholar 

  5. Aycan Z, Bas VN, Cetinkaya S, Agladioglu SY, Tiryaki T. Prevalence and long-term follow-up outcomes of testicular adrenal rest tumors in children and adolescent males with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2013;78(5):667–72.

    Article  Google Scholar 

  6. Gonzalez F, Chang L, Horab T, Lobo RA. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Fertil Steril. 1996;66(3):354–61.

    PubMed  CAS  Google Scholar 

  7. Carmina E, Gonzalez F, Chang L, Lobo RA. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol. 1995;85(6):971–6.

    Article  PubMed  CAS  Google Scholar 

  8. McGee WK, Bishop CV, Bahar A, Pohl CR, Chang RJ, Marshall JC, et al. Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome. Hum Reprod. 2012;27(2):531–40.

    Article  PubMed  CAS  Google Scholar 

  9. Mnif MF, Kamoun M, Mnif F, Charfi N, Kallel N, Ben Naceur B, et al. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Am J Med Sci. 2012;344(5):363–73.

    PubMed  Google Scholar 

  10. McNeilly AS, Colin Duncan W. Rodent models of polycystic ovary syndrome. Mol Cell Endocrinol. 2013;373:2–7

    Google Scholar 

  11. Ropelato MG, Rudaz MC, Escobar ME, Bengolea SV, Calcagno ML, Veldhuis JD, et al. Acute effects of testosterone infusion on the serum luteinizing hormone profile in eumenorrheic and polycystic ovary syndrome adolescents. J Clin Endocrinol Metab. 2009;94(9):3602–10.

    Article  PubMed  CAS  Google Scholar 

  12. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. Endocr Dev. 2008;13:145–58.

    Article  PubMed  CAS  Google Scholar 

  13. Williams RM, Ward CE, Hughes IA. Premature adrenarche. Arch Dis Child. 2012;97(3):250–4.

    Article  PubMed  Google Scholar 

  14. Idkowiak J, Lavery GG, Dhir V, Barrett TG, Stewart PM, Krone N, et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol. 2011;165(2):189–207.

    Article  PubMed  CAS  Google Scholar 

  15. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche–normal variant or forerunner of adult disease? Endocr Rev. 2000;21(6):671–96.

    Article  PubMed  CAS  Google Scholar 

  16. Abbott DH, Bird IM. Nonhuman primates as models for human adrenal androgen production: function and dysfunction. Rev Endocr Metab Disord. 2009;10(1):33–42.

    Article  PubMed  CAS  Google Scholar 

  17. Oberfield SE, Sopher AB, Gerken AT. Approach to the girl with early onset of pubic hair. J Clin Endocrinol Metab. 2011;96(6):1610–22.

    Article  PubMed  CAS  Google Scholar 

  18. Cisternino M, Dondi E, Martinetti M, Lorini R, Salvaneschi L, Cuccia M, et al. Exaggerated 17-hydroxyprogesterone response to short-term adrenal stimulation and evidence for CYP21B gene point mutations in true precocious puberty. Clin Endocrinol (Oxf). 1998;48(5):555–60.

    Article  CAS  Google Scholar 

  19. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997;82(12):4075–9.

    Article  PubMed  CAS  Google Scholar 

  20. Maliqueo M, Sir-Petermann T, Perez V, Echiburu B, de Guevara AL, Galvez C, et al. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3282–8.

    Article  PubMed  CAS  Google Scholar 

  21. Yoshida N, Sekiba K, Yanaihara T, Sano Y, Shibusawa H, Okinaga S, et al. Inhibition of fetal adrenal 21-hydroxylase by naturally occurring steroids. Endocrinol Jpn. 1978;25(4):349–53.

    Article  PubMed  CAS  Google Scholar 

  22. Kirschner MA, Jacobs JB. Combined ovarian and adrenal vein catheterization to determine the site(s) of androgen overproduction in hirsute women. J Clin Endocrinol Metab. 1971;33(2):199–209.

    Article  PubMed  CAS  Google Scholar 

  23. Wajchenberg BL, Achando SS, Okada H, Czeresnia CE, Peixoto S, Lima SS, et al. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test. J Clin Endocrinol Metab. 1986;63(5):1204–10.

    Article  PubMed  CAS  Google Scholar 

  24. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62(6):644–9.

    Article  CAS  Google Scholar 

  25. Chang RJ, Laufer LR, Meldrum DR, DeFazio J, Lu JK, Vale WW, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1983;56(5):897–903.

    Article  PubMed  CAS  Google Scholar 

  26. White D, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1995;42(5):475–81.

    Article  CAS  Google Scholar 

  27. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011;26(11):3138–46.

    Article  PubMed  CAS  Google Scholar 

  28. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic–pituitary–adrenal axis. J Clin Endocrinol Metab. 1998;83(7):2317–23.

    Article  PubMed  CAS  Google Scholar 

  29. Sahin Y, Kelestimur F. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation. Hum Reprod. 1997;12(5):910–3.

    Article  PubMed  CAS  Google Scholar 

  30. Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3558–66.

    Article  PubMed  CAS  Google Scholar 

  31. Gambineri A, Forlani G, Munarini A, Tomassoni F, Cognigni GE, Ciampaglia W, et al. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J Endocrinol Invest. 2009;32(3):210–8.

    PubMed  CAS  Google Scholar 

  32. Chang RJ, Mandel FP, Wolfsen AR, Judd HL. Circulating levels of plasma adrenocorticotropin in polycystic ovary disease. J Clin Endocrinol Metab. 1982;54(6):1265–7.

    Article  PubMed  CAS  Google Scholar 

  33. Glintborg D, Mumm H, Hougaard DM, Ravn P, Andersen M. Smoking is associated with increased adrenal responsiveness, decreased prolactin levels and a more adverse lipid profile in 650 white patients with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(3):170–4.

    Article  PubMed  CAS  Google Scholar 

  34. Gu F, Caporaso NE, Schairer C, Fortner RT, Xu X, Hankinson SE, et al. Urinary concentrations of estrogens and estrogen metabolites and smoking in caucasian women. Cancer Epidemiol Biomarkers Prev. 2013;22(1):58–68.

    Google Scholar 

  35. Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(6):1973–8.

    Article  PubMed  CAS  Google Scholar 

  36. Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011;96(3):623–31.

    Article  PubMed  CAS  Google Scholar 

  37. Schmidt J, Brannstrom M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96(7):2178–85.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montefiore Medical Center, 1695 Eastchester Road, Suite 307, Bronx, NY, 10461, USA

    Ruth Freeman M.D. (Professor of Medicine and Professor of Obstetrics Gynecology and Women’s Health)

Authors
  1. Ruth Freeman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruth Freeman M.D. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine Program for Polycystic Ovary Syndrome Yale Reproductive Endocrinology, New Haven, Connecticut, USA

    Lubna Pal

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Freeman, R. (2014). The Role of the Adrenal Glands in the Hyperandrogenism Associated with Polycystic Ovarian Syndrome. In: Pal, L. (eds) Polycystic Ovary Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8394-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8394-6_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8393-9

  • Online ISBN: 978-1-4614-8394-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation